The firm said it took in $33.6 million in product and service revenue in the quarter, a 42 percent increase from $23.6 million in Q4 2018.
Adaptive said that Q4 clinical testing volume for its ClonoSeq sequencing assay for minimal residual disease increased 66 percent to 3,218 tests.
The increase in total revenues was driven primarily by sales of Natera's Panorama and Horizon tests.
The comprehensive human vaginal gene catalog includes 950,000 non-redundant genes, and is functionally and taxonomically annotated.
Microbiome and immune features in the mouths of e-cigarette smokers, cigarette smokers, and controls revealed a rise in periodontal disease-related bugs and inflammation in vape users.
In the quarter, the firm entered a partnership with Specific Diagnostics and also submitted an enhanced version of its blood culture ID panel for regulatory clearance.
Billable test volume for the company's ConfirmMDx prostate cancer test fell 5 percent year over year, but global volume for its SelectMDx test rose 61 percent.
Oslo-based InstruNor's systems will enable Fluidigm to offer fully automated, walkaway sample preparation for flow and mass cytometry.
With the partnership, the companies aim to help researchers streamline their workflows from sample collection to enrichment to interpretation.
The firm posted $29.7 million in revenues, up about 15 percent from $25.8 million in Q4 2018 and slightly above the analysts' average estimate of $29.5 million.
Funded by a five-year, $3.7 million NIH grant, the firm plans to offer an assay that is cheaper and less invasive than standard upper endoscopies.
The collaboration will combine Twist's target enrichment and sample library preparation kits and Miroculus' Miro Canvas microfluidics system.
The company is developing an RNA sequencing kit based on a technology that enables barcoding in a test tube format to prepare samples for single-cell profiling.
The firm placed 45 of its T2Dx diagnostics instruments in 2019, but plans to reduce that number in 2020 to focus on instrument utilization.
The firm said its revenues for the three months ended Dec. 31, 2019 were $62.9 million compared to $32.9 million in the same quarter of 2018.
The company said it will use the proceeds for general corporate purposes, such as the repayment of debt, working capital, and possible acquisitions.
The Logix Smart Coronavirus COVID-19 test can now be sold as an IVD in markets that accept CE-marking as valid regulatory approval, the company said.
By sequencing ancient Salmonella enterica isolates, investigators retraced the history of the bug in humans transitioning to pastoral and agricultural lifestyles.
North Carolina-based BioSkryb develops sample preparation kits based on proprietary primary template-directed amplification chemistry.
The kits can detect more than 1,000 antimicrobial resistance gene variants, including mobilized colistin resistance (mcr) and extended-spectrum beta lactamases.
LGC will be Swift's worldwide partner for amplicon-based targeted sequencing assays for genotyping AgBio samples, including crop species and animals.
Last week, GenomeWeb's readers were most interested in Illumina asking a court for a preliminary injunction to prevent BGI from distributing sequencers in the US.
The company said it expects to launch the Verigene II system with respiratory and gastrointestinal assays in the middle of this year.
GenapSys will offer the Twist Bioscience products to customers of its recently launched low-cost, portable DNA sequencing system.
LabCorp will be the exclusive provider of the test, which uses next-generation sequencing to look for actionable mutations cell-free DNA in NSCLC patients.
A Minnesota toddler given a gene therapy to treat her spinal muscular atrophy is now walking, according to Newsweek.
NBC Bay Area reports a California lab has been certified to conduct forensic mitochondrial DNA sequencing.
The New York Times reports on how environmental DNA sampling could monitor endangered species.
In Cell this week: proteomic, genomic, and transcriptomic analysis of endometrial cancer; deep neural network learning-based approach to antibiotic discovery; and more.